Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 14, 2024

BUY
$0.22 - $0.66 $84 - $252
383 Added 1.78%
21,883 $8,000
Q2 2023

Jul 21, 2023

SELL
$1.02 - $1.89 $1,530 - $2,835
-1,500 Reduced 6.52%
21,500 $37,000
Q2 2021

Aug 04, 2021

SELL
$1.78 - $2.76 $1,178 - $1,827
-662 Reduced 2.8%
23,000 $57,000
Q2 2020

Jul 23, 2020

BUY
$0.56 - $1.41 $3,360 - $8,460
6,000 Added 33.97%
23,662 $31,000
Q1 2020

May 05, 2020

BUY
$0.51 - $1.08 $9,007 - $19,074
17,662 New
17,662 $11,000

Others Institutions Holding OTLK

About Outlook Therapeutics, Inc.


  • Ticker OTLK
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 226,144,992
  • Market Cap $1.17B
  • Description
  • Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-relate...
More about OTLK
Track This Portfolio

Track Creative Planning Portfolio

Follow Creative Planning and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Creative Planning, based on Form 13F filings with the SEC.

News

Stay updated on Creative Planning with notifications on news.